Drug profile · INN
lifitegrast
XIIDRA
lifitegrast (XIIDRA) is a integrin alpha-l/beta-2 (lfa-1) antagonist. Route of administration: ophthalmic. Current US regulatory status: approved.
Drug details — lifitegrast
- US status
- approved
- Class
- Sensory organs (S01)
- Route
- OPHTHALMIC
- Patents
- 0
- Programs
- 4
- Data quality
- 0.84
Quick answer
lifitegrast (XIIDRA) is a integrin alpha-l/beta-2 (lfa-1) antagonist. Route of administration: ophthalmic. Current US regulatory status: approved.
Key facts
Mechanism of action
Integrin alpha-L/beta-2 (LFA-1) antagonist
Primary target: Integrin alpha-L/beta-2 (LFA-1)
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | application withdrawn | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is lifitegrast?
lifitegrast (XIIDRA) is a integrin alpha-l/beta-2 (lfa-1) antagonist. Route of administration: ophthalmic. Current US regulatory status: approved.
What is the brand name for lifitegrast?
XIIDRA is a marketed brand name for lifitegrast. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of lifitegrast?
lifitegrast has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.